Recent Company News

• 05:48 AM ET Oct 31, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (85 total)

• 03:05 PM ET Oct 30, 2025
  

  Transcript Intelligence: Sandoz Group Q3 Sales and Revenue Themes (CHF52.90, 0.00)

• 03:05 PM ET Oct 30, 2025
  

  Transcript Intelligence: Sandoz Group Q3 Sales and Revenue Guidance (CHF52.90, 0.00)

• 03:05 PM ET Oct 30, 2025
  

  Transcript Intelligence: Sandoz Group Q3 Sales and Revenue Q&A (CHF52.90, 0.00)

• 03:58 AM ET Oct 30, 2025
  

  StreetAccount Summary - European pre-market trading update

• 02:07 AM ET Oct 30, 2025
  

  Sandoz Group reports Q3 revenue $2.83B vs FactSet $3.09B [3 est, $2.85-3.57B] (CHF 50.68, 0.00)

• 01:12 PM ET Oct 29, 2025
  

  HHS issues press release on accelerating biosimilar drug development and lowering drug prices

• 09:21 AM ET Oct 29, 2025
  

  FDA announces draft guidance for biosimilar development

• 04:51 AM ET Oct 29, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (82 total)

• 04:40 AM ET Oct 01, 2025
  

  European healthcare boosted by easing regulatory uncertainty following Pfizer-US deal: